



FINDING COMMON GROUND IN APPROACHES TO MEASURING VALUE IN HEALTHCARE

Grounded in the principles of patient-centricity, transparency, and open-source modeling, the **Innovation and Value Initiative (IVI)** is a recognized leader within the value and health technology assessment community.

IVI's **MISSION** is to advance the science, practice, and use of value assessment in healthcare to make it more meaningful to those who receive, provide, and pay for care.

IVI's **VISION** is a U.S. healthcare system that directs resources to the most valuable treatments for every individual patient, to the benefit of all stakeholders.



Advancing Patient-Centered Value Assessment

LEARNING LABORATORY



Creating open-source disease-specific models to test new methods, drive discourse, and generate tools for the broader field

CONVENING



"Connecting the dots" and creating meaningful action-focused discussion

TARGETED RESEARCH



Focused research projects to develop methods, address evidence gaps, and explore applications in real-world decision-making

THOUGHT LEADERSHIP



Asking hard questions and driving progress in debates around policy, science, and health equity



SELECT PUBLICATIONS

1. Bright, J. and A. Balch. "Health Care Value Through the Lens of Patient's Well-Being." *Health Affairs Forefront Blog*. March 2022. Available: <https://www.healthaffairs.org/doi/10.1377/forefront.20220228.656900> (final piece in 11-part series).
2. Bright, J. "Patient Value Is the Root of a Learning Health System." *American Journal of Accountable Care*. 2021;9(4):34-36. DOI: <https://doi.org/10.37765/ajac.2021.88805>.
3. Courtney, C., Phillips, L., Masco, R., O'Hara Levi, S., Bright, J., Eller, J., Hyde, A., Kelly, M., and Malik, E. "First-Hand Perspectives in Rheumatoid Arthritis: Insights to Improve Healthcare Research & Value Assessment." *Innovation and Value Initiative*. October 2021. Available: https://www.thevalueinitiative.org/wp-content/uploads/2021/10/First-Hand-Perspectives-in-Rheumatoid-Arthritis_FINAL.pdf.
4. Innovation and Value Initiative. Public comments submitted to ICER on its draft COVID-19 Report. March 2022. Available: <https://www.thevalueinitiative.org/press-release-ivi-submits-comments-to-icer-draft-covid-19-report/>.
5. Van den Broek, R., Matheis, R., Bright, J., Hartog, T., and Perfetto, E. "Value-based Evidence Across Health Care Sectors: A Push for Transparent Real-World Studies, Data, and Evidence Dissemination." *Health Economics, Policy and Law*. April 2022. DOI: <https://doi.org/10.1017/S1744133122000056>.
6. Xie, R., Dosreis, S., Regnante, JM, Neslusan, C., Malik, ED, and Bright, JL. "POSB370 Strategies to Include Underrepresented Patient Populations in Patient-Centered Research. *Value In Health*. 2022;25(S233). DOI: <https://doi.org/10.1016/j.jval.2021.11.1137>.
7. Xie RZ, Malik E deFur, Linthicum MT, Bright JL. "Putting Stakeholder Engagement at the Center of Health Economic Modeling for Health Technology Assessment in the United States." *PharmacoEconomics*. 2021;39(6):631-638. Available: <https://link.springer.com/article/10.1007/s40273-021-01036-3>.
8. Xie, R., Towse, A., and Garrison, L. "Should We Pay for Scientific Knowledge Spillovers? The Underappreciated Value of 'Failed' R&D Efforts." *International Journal of Technology Assessment in Health Care*. 2022;38(1), E31. DOI: <https://doi.org/10.1017/S0266462322000150>.

IVI members are true partners in advancing the science of value assessment. To learn more about how you can be a member, go to www.thevalueinitiative.org.

